Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
We’re pleased to announce the MHRA has given notice of validation of our MAA for HMTM, a 4 mg oral tablet for the treatment of mild cognitive impairment (MCI-AD) and mild to moderate Alzheimer’s disease. We look forward to sharing further updates.